-
India's Iyer says 'getting better by the day' after lacerated spleen
-
Yesavage fairytale carries Blue Jays to World Series brink
-
Bank of Japan keeps interest rates unchanged
-
Impoverished Filipinos forge a life among the tombstones
-
Jokic posts fourth straight triple-double as Nuggets rout Pelicans
-
UN calls for end to Sudan siege after mass hospital killings
-
Teenage Australian cricketer dies after being hit by ball
-
As Russia advances on Kupiansk, Ukrainians fear second occupation
-
Trade truce in balance as Trump meets 'tough negotiator' Xi
-
China to send youngest astronaut, mice on space mission this week
-
Yesavage gem carries Blue Jays to brink of World Series as Dodgers downed
-
With inflation under control, ECB to hold rates steady again
-
Asia stocks muted with all eyes on Trump-Xi meeting
-
Personal tipping points: Four people share their climate journeys
-
Moto3 rider Dettwiler 'no longer critical' after crash: family
-
US economy in the dark as government shutdown cuts off crucial data
-
Trump orders nuclear testing resumption ahead of Xi talks
-
'Utter madness': NZ farmers agree dairy sale to French group
-
Samsung posts 32% profit rise on-year in third quarter
-
30 years after cliffhanger vote, Quebec separatists voice hope for independence
-
Taxes, labor laws, pensions: what Milei wants to do next
-
South Sudan's blind football team dreams of Paralympic glory
-
US says 4 killed in new strike on alleged Pacific drug boat
-
What we do and don't know about Rio's deadly police raid
-
'They slit my son's throat' says mother of teen killed in Rio police raid
-
Arteta hails 'special' Dowman after 15-year-old makes historic Arsenal start
-
Google parent Alphabet posts first $100 bn quarter as AI fuels growth
-
Underwater 'human habitat' aims to allow researchers to make weeklong dives
-
Maresca slams Delap for 'stupid' red card in Chelsea win at Wolves
-
'Non-interventionist' Trump flexes muscles in Latin America
-
Slot defends League Cup selection despite not meeting 'Liverpool standards'
-
'Poor' PSG retain Ligue 1 lead despite stalemate and Doue injury
-
Liverpool crisis mounts after League Cup exit against Palace
-
Kane scores twice as Bayern set European wins record
-
Radio Free Asia suspends operations after Trump cuts and shutdown
-
Meta shares sink as $16 bn US tax charge tanks profit
-
Dollar rises after Fed chair says December rate cut not a given
-
Google parent Alphabet posts first $100 bn quarter as AI drives growth
-
Rob Jetten: ex-athlete setting the pace in Dutch politics
-
Juve bounce back after Tudor sacking as Roma keep pace with leaders Napoli
-
Favorite Sovereignty scratched from Breeders' Cup Classic after fever
-
Doue injured as PSG held at Lorient in Ligue 1
-
Leverkusen win late in German Cup, Stuttgart progress
-
Jihadist fuel blockade makes life a struggle in Mali's capital
-
Uber plans San Francisco robotaxis in Waymo challenge
-
Paramilitary chief vows united Sudan as his forces are accused of mass killings
-
Trump, Xi to meet seeking truce in damaging trade war
-
Divided US Fed backs second quarter-point rate cut of 2025
-
'Amazing' feeling for Rees-Zammit on Wales return after NFL adventure
-
'Cruel' police raids help, not hinder, Rio's criminal gangs: expert
US approves first at-home cervical cancer screening device
The US Food and Drug Administration has approved an at-home cervical cancer screening tool as an alternative to Pap smears by a gynecologist, the company behind the device said Friday.
The "Teal Wand" -- a self-collection vaginal swab shaped like a tampon and developed by Teal Health -- will be available online for individuals aged 25 to 65 who are at average risk for cervical cancer.
Users request a kit online, have a brief visit with a telehealth provider to gauge eligibility and then the kit is prescribed. They then collect the sample and ship it to a lab for analysis.
Cervical cancer, which affects the lower part of the uterus, is diagnosed in about 0.6 percent of women. Although HPV vaccination and regular screening are highly effective at preventing the disease, more than one in four women fall behind on routine appointments.
"When we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day," Teal Health CEO Kara Egan said in a statement.
The Teal Wand tests for high-risk strains of human papillomavirus (HPV), the primary cause of cervical cancer.
A large clinical trial found its accuracy comparable to a traditional Pap smear, which requires a speculum and is often cited as a barrier to screening due to discomfort.
Most sexually active people will contract HPV at some point, though only a small fraction develop cancer.
Teal Health did not disclose pricing but said it is in talks with insurers to ensure affordability. The product will launch first in California in June.
L.Maurer--VB